SFI
ERNA icon

Susquehanna Fundamental Investments’s Eterna Therapeutics ERNA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$66K Sell
4
-1
-20% -$19K ﹤0.01% 1480
2021
Q4 		$165K Sell
5
-2
-29% -$109K ﹤0.01% 1282
2021
Q3 		$468K Buy
+7
New +$604K 0.01% 1245

Other funds holding ERNA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna Fundamental Investments's ERNA Position: Q1 2022 in Review

Susquehanna Fundamental Investments reduced its Eterna Therapeutics (ERNA) stake by 20% in Q1 2022, selling an estimated $19K and leaving 4 shares worth $66K. The position accounts for ﹤0.01% of the portfolio, ranked #1480.

Susquehanna Fundamental Investments first reported a position in ERNA in Q3 2021 and has held it in 3 quarters since. The position peaked at $468K in Q3 2021. 49 funds tracked by Wall St. Rank hold ERNA as of Q1 2022.

  • Susquehanna Fundamental Investments held 4 shares of Eterna Therapeutics worth $66K as of Q1 2022.
  • Susquehanna Fundamental Investments sold 1 Eterna Therapeutics share in Q1 2022, an estimated $19K.
  • Eterna Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1480 holding.
  • Susquehanna Fundamental Investments first reported a position in Eterna Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • Susquehanna Fundamental Investments's Eterna Therapeutics position peaked at $468K in Q3 2021.
  • 49 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.